common.study.topics.clinical

Treatment of Ulcerative Colitis

common.study.values.description

A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Study M15-722 is a Phase 2a study to investigate the efficacy and safety of ABBV-323 in participants with moderate to severe UC who failed prior therapy.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - ABBV-323 Dose A

ABBV-323 Dose A is intravenously (IV) administered.

Drug - ABBV-323 Dose B

ABBV-323 Dose B is administered subcutaneously (SC).

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of ABBV-323 in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

common.study.values.clinical-trial-id

NCT03695185

participant.views.study.view.id

e73pje